If you searched “tesamorelin before and after,” you were probably hoping to find side-by-side transformation photos or testimonials. We are not going to show you any. On a research-use-only reference site, staged before/after images and personal anecdotes are not evidence — and for a compound like tesamorelin they are almost always misleading. Instead, here is the honest version: what actual peer-reviewed clinical trials measured, over what time frame, in which people, and where the data simply does not exist.
The short answer up front: tesamorelin has genuinely strong clinical evidence, but only in one specific setting — adults with HIV-associated lipodystrophy (excess visceral abdominal fat linked to HIV and its treatment). Nearly all of the “before and after” you see online extrapolates from that narrow, well-studied population to general cosmetic or bodybuilding use, where controlled human data is essentially absent.
What the research shows over time
The measured effect that trials consistently document is a reduction in visceral adipose tissue (VAT) — deep abdominal fat quantified by CT or MRI scans, not by how someone looks in a mirror. The change is gradual and reverses when the drug is stopped.
| Study (author, year) | Population | Duration | What was measured |
|---|---|---|---|
| Falutz et al., 2010 (J Acquir Immune Defic Syndr) | 404 HIV patients with abdominal fat | 6 months (+6-month extension) | VAT fell ~10.9% (−21 cm²) at 6 months, ~18% at 12 months; IGF-1 rose; no glucose worsening |
| Falutz et al., 2008 (AIDS) | ~410 HIV patients randomized (26-wk phase + extension) | 52 weeks | VAT reduction sustained at ~18% on treatment; fat re-accumulated after stopping |
| Stanley et al., 2014 (JAMA) | 48 HIV patients with abdominal fat | 6 months | VAT −34 cm²; liver fat −2.0% (net −2.9% vs placebo) |
| Stanley et al., 2019 (Lancet HIV) | 61 HIV patients with fatty liver | 12 months | Hepatic fat −37% relative; 35% reached normal liver fat vs 4% on placebo |
| Badran et al., 2026 (meta-analysis, 5 RCTs) | Pooled HIV lipodystrophy trials | Varied (26–52 weeks) | VAT −27.7 cm²; lean mass +1.4 kg; no significant change in BMI or subcutaneous fat |
A rough timeline from these trials: a small, transient rise in fasting glucose can appear within the first two weeks (Stanley et al., 2014); IGF-1 (a growth-hormone marker) climbs early; measurable visceral-fat reduction accrues over roughly three to six months and, where studied, continues modestly to twelve months (Falutz et al., 2010). Crucially, the benefit is not durable — when tesamorelin was stopped, visceral fat re-accumulated (Falutz et al., 2008).
A clear distinction on evidence type: all of the above is clinical (randomized, placebo-controlled human trials), but confined to the HIV-lipodystrophy setting. Use in healthy adults for physique or “toning” is off-label and anecdotal — supported by no controlled human trials that we could locate. There is no reliable preclinical or clinical basis for the dramatic cosmetic “before and after” narratives common on forums.
Realistic expectations
What the data does support: in a specific clinical population, tesamorelin reduces deep visceral and liver fat, modestly increases lean mass, and raises IGF-1 (Badran et al., 2026). What it does not support: meaningful changes in overall body weight or BMI (the meta-analysis found none), reductions in the subcutaneous fat you can pinch, or any permanent “transformation.” Because the effect is measured on internal scans and largely reverses off-treatment, a photograph cannot honestly capture it.
This is exactly why online before/after photos for research compounds are unreliable: they are unverifiable, uncontrolled, subject to lighting/posing/dehydration tricks, frequently confound tesamorelin with diet, training, or other compounds, and often come from sellers. Individual response also varies widely by baseline fat, dose, and adherence. A photo proves nothing about a compound whose real endpoint is a CT-measured fat area.
Safety & legal status
Tesamorelin is a real, FDA-approved prescription drug — sold as Egrifta — but only for reducing excess abdominal fat in HIV-associated lipodystrophy (Dhillon, 2011). It is not approved for weight loss, anti-aging, bodybuilding, or general cosmetic use.
Reported adverse effects in trials include arthralgia (joint pain), myalgia, paresthesia (tingling), injection-site reactions, fluid retention, and transient increases in blood glucose (Badran et al., 2026; Stanley et al., 2014). Growth-hormone-axis stimulation warrants caution in anyone with diabetes, glucose intolerance, or a history of cancer. Long-term safety outside the studied HIV population is not established.
Material referenced here concerns tesamorelin as a research chemical for laboratory use only. It is not medical advice, not a treatment recommendation, and nothing on this page should be read as a claim that any product produces human “before and after” results. Consult a licensed clinician for any medical decision.
Dosage reference
Dosing in the published HIV trials was standardized at 2 mg subcutaneously once daily. If you are documenting reconstitution and measured dosing for research purposes, see our Tesamorelin dosage chart for vial-specific reconstitution figures, and use the peptide dosage calculator to convert concentration to draw volume. These are reference tools only, not a protocol to follow on yourself.
FAQ
Are there real tesamorelin before/after photos?
Not credible ones. Clinical trials measured internal visceral and liver fat with CT/MRI scans, not photographs. Any before/after images circulating online are unverified anecdotes and are not part of the peer-reviewed evidence, so we do not publish them.
How long until changes appeared in studies?
Measurable visceral-fat reduction developed over roughly three to six months of daily use in HIV patients, with modest additional change by twelve months (Falutz et al., 2010). IGF-1 rose earlier. There was no overnight or dramatic short-term “transformation.”
Do the results last after stopping?
No. In the extension trials, visceral fat re-accumulated once tesamorelin was discontinued (Falutz et al., 2008), so any effect depends on continued use rather than being a permanent change.
